September 26, 2024

TerraTrust nominated for the DQS Sustainability Award 2024 in the “Sustainable Innovation” category

TerraTrust nominated for the DQS Sustainability Award 2024 in the “Sustainable Innovation” category

We are pleased to announce significant news: the first sustainable and biodegradable pregnancy test in Europe developed by Zamann Pharma Support, under the Terra Trust house brand, has been nominated for the prestigious DQS Sustainability Award 2024 in the “Sustainable Innovation” category. This nomination is a confirmation of their tireless commitment to environmental protection and sustainable innovation.

Every year, the DQS Sustainability Awards recognize companies that are pioneers in sustainability. It is one of the most important awards in the field of sustainability, recognizing companies, regardless of their size, for their innovative approaches to promoting environmental protection and social responsibility. This nomination is not only a recognition for Terra Trust, but underscores how necessary sustainable solutions have become in all areas of life, including the healthcare industry.

For Terra Trust, this nomination symbolizes much more than just a recognition of their technical innovation. It highlights the growing importance of environmental protection in a sector traditionally characterized by plastic waste and environmentally harmful disposables. Their product represents a new generation of pregnancy tests that protect the environment without compromising on quality or accuracy.

More Information in German / Original News:

Our latest News

discover more
PRAME-specific T-cell therapy in an adolescent with metastatic kidney tumor

PRAME-specific T-cell therapy in an adolescent with metastatic kidney tumor

Researchers and physicians at the Hopp Children’s Cancer Center Heidelberg (KiTZ) and other leading cancer centers report an exceptional treatment success in an adolescent with an advanced, therapy-resistant kidney tumor. Using a novel, personalized T-cell therapy, they succeeded in completely pushing back the tumor disease despite multiple metastases. The individual compassionate-use treatment has now been […]

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, before the open of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on August 13, 2026, at 8:00 a.m. Eastern Time (ET) to discuss […]

Can Protein Building Blocks Protect Against Vascular and Kidney Damage?

Can Protein Building Blocks Protect Against Vascular and Kidney Damage?

Researchers from the Medical Faculty Heidelberg, the Medical Faculty Mannheim, and the Centre for Organismal Studies (COS) at Heidelberg University have launched a new research project investigating so-called dipeptides. Some of these naturally occurring protein building blocks are able to neutralize toxic metabolic by-products and may therefore help protect against vascular and kidney damage, particularly […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp